Norris Medicines Faces Evaluation Shift Amid Mixed Financial Indicators and Market Challenges
Norris Medicines, a microcap in the Trading & Distributors sector, has experienced a recent adjustment in its evaluation score due to changing technical trends. Despite a strong annual return, the company faces challenges such as a negative book value, declining net sales, and high debt levels, complicating its market position.
Norris Medicines, a microcap company in the Trading & Distributors industry, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a mildly bullish stance to a mildly bearish outlook. The company's current stock price stands at 18.14, down from a previous close of 19.00. Over the past year, Norris Medicines has demonstrated a notable return of 54.38%, significantly outperforming the BSE 500 index, which returned 3.95%. However, the company faces challenges, including a negative book value and a weak long-term fundamental strength, as evidenced by a decline in net sales at an annual rate of -5.78% over the past five years.
Despite the recent performance, Norris Medicines is characterized by high debt levels, with a debt-to-equity ratio averaging 0 times. The stock's technical indicators present a mixed picture, with the MACD showing bullish signals on both weekly and monthly charts, while moving averages indicate bearish trends.
Overall, the adjustment in evaluation reflects the complexities surrounding Norris Medicines' market position and financial metrics.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
